Immunovant, Inc. Common Stock

Day range

$27.63 – $28.50

Open

$28.46

Prev close

$28.41

Volume

409.25K

Market cap

$5.87B

Shares out

206.55M

P/E

—

P/S

—

P/B

7.98

P/FCF

—

ROE

-73.2%

ROA

-63.1%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Director appointmentSep 3, 2026

  Jacob Bauer, Douglas Hughes and Robert Susman were each elected to serve as a member of Immunovant's Board of Directors (the "Board"), until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified.

• Public offeringDec 12, 2025

  On December 10, 2025, Immunovant, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Leerink Partners LLC ("Leerink Partners"), relating to the issuance and sale in an underwritten offering by the Company of 26.2 million shares (the "Shares") of the Company's common stock, par value $0.0001 per share (the "Common Stock"), at an offering price of $21.00 per share.

• Public offeringDec 11, 2025

  On December 10, 2025, Immunovant, Inc. (the "Company") announced the pricing of an underwritten offering of its common stock, with anticipated gross proceeds to the Company of approximately $550 million, before deducting underwriting discounts and commissions and other expenses payable by the Company in connection with the transaction.

• Executive compensation changeNov 21, 2025

  The Company has entered into a Separation Agreement and General Release ("Separation Agreement") with Dr. Geffner, pursuant to which Dr. Geffner will receive severance benefits in accordance with the existing terms of his employment agreement with the Company, dated January 9, 2024... the Separation Agreement provides that Dr. Geffner will provide certain consulting services to the Company through April 30, 2026 (the "Consulting Period"). Subject to Dr. Geffner's continued service during the Consulting Period, Dr. Geffner's outstanding equity awards will continue to vest in accordance with their terms and, in the event of a change in control of the Company during the Consulting Period, any then unvested equity awards that were scheduled to vest during the Consulting Period will immediately vest in full upon such change in control.

• Investor presentationSep 3, 2025

  On September 3, 2025, the Company posted a presentation regarding the update on its GD proof-of-concept study on the "Presentations" page of its investor relations website at https://www.immunovant.com/investors and will host a conference call and webcast to discuss the remission data from the GD trial.

Days to cover

9.6

Short interest

17.42M

Avg volume

1.81M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
  neutralGlobeNewswire Inc.· Oct 21, 2026
• Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight
  positiveGlobeNewswire Inc.· Jun 22, 2026
• Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight
  positiveGlobeNewswire Inc.· Jun 2, 2026
• Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight
  positiveGlobeNewswire Inc.· Apr 15, 2026
• Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
  negativeGlobeNewswire Inc.· Apr 2, 2026